Protara Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures
Protara Therapeutics, Inc. (TARA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures of 706.00 thousand shares for the 6-month period ending 2017-06-30, per its 10-Q filed 2017-08-07.
Discontinued › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod · last filed 2017-08-07
- Protara Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2017-06-30 was 46.66K shares, a 55.20% decline year-over-year.
- Protara Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2017-03-31 was 659.34K shares, a 6493.42% increase year-over-year.
- Protara Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2016-12-31 was 13.33K shares, a 96.83% decline year-over-year.
- Protara Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2016-09-30 was 5.00K shares, a 92.11% decline year-over-year.
- Protara Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2016 was 132.50K shares, a 86.89% decline from fiscal 2015.
- Protara Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2015 was 1.01M shares, a 53.10% increase from fiscal 2014.
- Protara Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2014 was 659.87K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 12 month |
|---|---|---|---|---|
| 2017-06-30 | 46.66K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | 706.00K shares 10-Q · filed 2017-08-07 | 719.34K shares derived: sum of 3 quarters · filed 2017-08-07 | 724.34K shares derived: sum of 4 quarters · filed 2017-08-07 |
| 2017-03-31 | 659.34K shares 10-Q · filed 2017-05-10 | 672.67K shares derived: sum of 2 quarters · filed 2017-05-10 | 677.67K shares derived: sum of 3 quarters · filed 2017-05-10 | 781.84K shares derived: sum of 4 quarters · filed 2017-05-10 |
| 2016-12-31 | 13.33K shares derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | 18.33K shares derived: sum of 2 quarters · filed 2017-03-16 | 122.50K shares derived: sum of 3 quarters · filed 2017-03-16 | 132.50K shares 10-K · filed 2017-03-16 |
| 2016-09-30 | 5.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | 109.16K shares derived: sum of 2 quarters · filed 2016-11-07 | 119.16K shares 10-Q · filed 2016-11-07 | 539.49K shares derived: sum of 4 quarters · filed 2016-11-07 |
| 2016-06-30 | 104.16K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | 114.16K shares 10-Q · filed 2016-08-08 | 534.49K shares derived: sum of 3 quarters · filed 2016-08-08 | 597.83K shares derived: sum of 4 quarters · filed 2016-08-08 |
| 2016-03-31 | 10.00K shares 10-Q · filed 2016-05-09 | 430.33K shares derived: sum of 2 quarters · filed 2016-05-09 | 493.67K shares derived: sum of 3 quarters · filed 2016-05-09 | 620.33K shares derived: sum of 4 quarters · filed 2016-05-09 |
| 2015-12-31 | 420.33K shares derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-14 | 483.67K shares derived: sum of 2 quarters · filed 2016-03-14 | 610.33K shares derived: sum of 3 quarters · filed 2016-03-14 | 1.01M shares 10-K · filed 2016-03-14 |
| 2015-09-30 | 63.33K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | 190.00K shares derived: sum of 2 quarters · filed 2015-11-12 | 589.92K shares 10-Q · filed 2015-11-12 | |
| 2015-06-30 | 126.66K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-13 | 526.59K shares 10-Q · filed 2015-08-13 | ||
| 2015-03-31 | 399.93K shares 10-Q · filed 2015-05-13 | |||
| 2014-12-31 | 659.87K shares 10-K · filed 2015-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |